DNMT1 and acute myeloid leukemia: Two drugs that inhibit DNMT (DNMTi), azacitidine and decitabine, were approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for treatment of myelodysplastic syndrome and acute myeloid leukemia (AML).